Trial
NCT03676231
Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Second Genome
Collaborators
—
Condition
Nonalcoholic Steatohepatitis
Intervention
SGM-1019
Why stopped
Study terminated due to a safety event which rendered the risk-benefit profile in NASH to no longer be adequately favorable
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-07-11